Asciminib Treatment Optimization in ≥ 3rd Line CML-CP
Novartis
Novartis
Takeda
Gamida Cell ltd
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Novartis
Thomas Jefferson University
Novartis
Novartis
Stanford University
Masonic Cancer Center, University of Minnesota
American Regent, Inc.
Masonic Cancer Center, University of Minnesota
Thomas Jefferson University
Novartis
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
Stanford University
Northwestern University
Novartis
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Washington University School of Medicine
Pfizer
University of Nebraska
M.D. Anderson Cancer Center
University of Nebraska
Center for International Blood and Marrow Transplant Research
Stanford University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Northside Hospital, Inc.
Fred Hutchinson Cancer Center
Fate Therapeutics
Karyopharm Therapeutics Inc
Medical College of Wisconsin
Memorial Sloan Kettering Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Alabama at Birmingham
Novartis
Pfizer
Takeda
Pfizer
Teva Branded Pharmaceutical Products R&D, Inc.
Duke University
H. Lee Moffitt Cancer Center and Research Institute
Medical College of Wisconsin
H. Lee Moffitt Cancer Center and Research Institute
Novartis